Drug Profile

Cemsidomide - C4 Therapeutics

Alternative Names: CFT 7455

Latest Information Update: 07 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator C4 Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

01 Oct 2025 C4 Therapeutics and Pfizer agree to co-develop Cemsidomide for Multiple myeloma
01 Oct 2025 C4 Therapeutics plans a phase Ib trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) (PO), in the second quarter of 2026
01 Oct 2025 C4 Therapeutics plans a phase III trial for Multiple myeloma (Combination therapy) .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com